https://www.selleckchem.com/pr....oducts/reparixin-rep
The phase 3 trial PALISADE, comparing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) oral immunotherapy versus placebo in peanut-allergic children, reported that a significantly higher percentage of PTAH-treated participants tolerated higher doses of peanut protein after 1year of treatment. This study used PALISADE data to estimate the reduction in the risk of systemic allergic reaction (SAR) after accidental exposure following 1year of PTAH treatment. Participants (aged 4-17years) enrolled in PALISADE were included.
Like
Comment
Share
